Korea University Anam Hospital, Seoul, Republic of Korea.
Korea Disease Control and Prevention Agency, Cheongju, Korea.
Vaccine. 2022 Jan 31;40(5):691-694. doi: 10.1016/j.vaccine.2021.12.044. Epub 2021 Dec 24.
In South Korea, all 12th grade students (highs school seniors) were offered BNT162b2 vaccine starting July 19, 2021; while 10-11th grade students were not eligible. We conducted a nationwide retrospective cohort study by to determine the safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents against SARS-CoV-2 infection. Among 444,313 persons who received the first dose of vaccine, reporting rate for myocarditis and/or pericarditis was 1.8 per 100,000 (95% C.I. 0.8-3.5) among first-dose recipients and 4.3 per 100,000 (95% C.I. 2.6-6.7) in second-dose recipients. Vaccine effectiveness against symptomatic/asymptomatic SARS-CoV-2 infection 14 days post-first dose vaccination was 91.1% (95% C.I. 89.6-92.5), and 14 days post-second dose was 99.1% (95% C.I. 98.5-99.5). In this retrospective cohort study, BNT162b2 vaccination was safe and was associated with a significantly lower risk of SARS-CoV-2 infection, suggesting that vaccination in adolescent may reduce the burden of Covid-19.
在韩国，从 2021 年 7 月 19 日开始，所有 12 年级学生（高中高年级学生）都接种了 BNT162b2 疫苗；而 10-11 年级学生则没有资格接种。我们进行了一项全国性的回顾性队列研究，以确定 BNT162b2 mRNA Covid-19 疫苗在青少年中的安全性和有效性，以预防 SARS-CoV-2 感染。在接受第一剂疫苗的 444,313 人中，心肌炎和/或心包炎的报告率为每 10 万人 1.8 例（95%CI0.8-3.5），第二剂疫苗的报告率为每 10 万人 4.3 例（95%CI2.6-6.7）。第一剂疫苗接种后 14 天对有症状/无症状 SARS-CoV-2 感染的疫苗有效性为 91.1%（95%CI98.6-92.5），第二剂疫苗接种后 14 天为 99.1%（95%CI98.5-99.5）。在这项回顾性队列研究中，BNT162b2 疫苗接种是安全的，与 SARS-CoV-2 感染的风险显著降低相关，这表明在青少年中接种疫苗可能会减轻 Covid-19 的负担。
